f8k_012413.htm
UNITED-STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
__________________________
 
FORM 8-K
__________________________
 
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):    January 18, 2013

 
UNITED-GUARDIAN, INC.
(Exact name of Registrant as Specified in Charter)
 
DELAWARE
1-10526
11-1719724
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
 
230 Marcus Boulevard, Hauppauge, New York
11788
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code:    (631) 273-0900
 
                                    Not Applicable                                      
(Former name or former address, if changed since last report)
 

 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
¨   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
 
 

 
Item 1.01.    Entry into a Material Definitive Agreement

 
On January 18, 2013 United-Guardian, Inc. (the “Company”) and Hospira Worldwide, Inc. (“Hospira”), executed a Settlement Agreement and General Release (the “Settlement Agreement”), settling a dispute in regard to the manufacture of Renacidin Irrigation, one of the Company’s pharmaceutical products, which was being manufactured by Hospira for the Company.  The Settlement Agreement provides for a lump sum payment to the Company of $518,050 for 2012 and a payment to the Company of $97,610 per month beginning January 2013 and continuing until either production is resumed or until Hospira’s supply agreement with the Company ends in January 2014.  In exchange for these payments the Company released Hospira from all claims up to the date of the Agreement.  Additional details on the Settlement Agreement can be found in Exhibit 10.1 attached hereto.
 

Item 9.01.    Financial Statements and exhibits.

(d)  
Exhibits.

10.1 Settlement Agreement and General Release executed January 18, 2013 and effective as of December 31, 2012 between United-Guardian, Inc. and Hospira Worldwide, Inc.


 
 
 

 
SIGNATURES

 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
UNITED-GUARDIAN, INC.
 
 
By:        /s/ Kenneth H. Globus
Name:   Kenneth H. Globus
Title:     President
 
January 23, 2013